TX-KAHUNA-WORKFORCE
Kahuna Workforce Solutions, the leading provider of skills and competency management software, has formed a strategic partnership with Norwegian operating services provider PXO AS to accelerate workforce competency in Norway’s booming energy sector, which is a significant stabilizer of the world’s oil and gas supply, particularly in meeting European demand.
The two companies, both of which already have established customers in Norway, have identified opportunities to jointly support the region’s growing demand for technically skilled professionals in the energy sector. The partnership specifically aims to improve operations readiness and assurance by combining Kahuna’s dynamic, digitized competency management platform with PXO’s extensive technical and field experience in a variety of operating production facilities offshore and onshore.
“PXO represents everything we look for in a partner as we strive to ensure successful and rapid adoption of competency-based training and development programs,” said Jai Shah, CEO of Kahuna Workforce Solutions. “As a company that works with many of the same customers as PXO, we’ve seen their expertise firsthand. It is clear they are the right partner to help us not only address the current needs of the energy industry but also pioneer innovative solutions that will shape the future of competency readiness and assurance in Norway.”
The collaboration comes at a critical time for the region, as Norway expects to draw nearly $22 billion in investments from oil and gas companies in 2024. The country is also leading the world toward cleaner energy solutions. Kahuna and PXO’s partnership will help Norwegian energy companies navigate this transition in a variety of ways, including streamlining skills validation and aligning operational standards with expanding ESG initiatives and emerging technologies.
“Just as we serve as a bridge between project and operation phases, Kahuna equips enterprises with validated competency data,” said Leif Olav Moe, CEO of PXO. “By uniting our technical and operational expertise with their cutting-edge competency management solutions, we are delivering a unique solution unlike anything the market has yet to provide—signifying our commitment to building a more skilled and competitive workforce to ascertain safer and more efficient operations.”
"At Kahuna, we are empowering organizations throughout the energy value chain by providing validated competency data and unique insights. This enables a deep understanding of workforce capabilities for seamless operational execution, in addition to aligning talent supply with demand and maximizing the return on investment in technical training,” Shah said. “When you combine our capabilities with PXO’s extensive experience in supporting operations with strategic training and competency services, there is no other competency management solution that comes close to building a skilled, safe, compliant, and competitive workforce.”
About Kahuna Workforce Solutions
Kahuna Workforce Solutions is the only skills management software built for operations, learning, and human resources. Kahuna equips enterprise organizations with validated skills data to understand workforce capability, align talent supply and demand, and increase the return on training investment. Across a wide array of industries including healthcare, energy, manufacturing, and aerospace, Kahuna helps organizations build a more skilled, competitive workforce. For more information, visit https://kahunaworkforce.com/.
About PXO
PXO's services are mainly within the petroleum industry with field operating companies as clients, however, the services are also applied within other industry segments, such as shipping, renewable energy and aquaculture.
PXO increases awareness of safety barriers and their functions to improve efficiency and safety in field operations. Exposed to increasingly demanding requirements from authorities, clients, suppliers, and other stakeholders as regards knowledge and experience require systematic and targeted competence development of operations personnel in particular, extending from planning through construction & start-up and into regular operations. PXO ensures that prevailing competence requirements are met and followed up through various measures:
- Systematization of specific competence requirements
- Development of model-based interactive management tools (portal solutions)
- Harmonization of job descriptions and work processes
- Development and execution of training plans through interactive computer based training and practical On the Job Training (OJT) programmes.
PXO is focused on the interaction between people, organization and technology as a means to optimize, integrate and align work processes and technical equipment for robust and safe overall solutions.
For more information, visit https://www.pxo.no/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240206626623/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom